Mgr. Pavel Němec, Ph.D.
Institute of Biostatistics and Analyses
e‑mail: |
---|
Total number of publications: 102
2007
-
Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy
Hematologica/The Hematology Journal, year: 2007
-
Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma?
Blood reviews, year: 2007
-
Genetic lesions in multiple myeloma: prognostic and predictive significance in the era of the new drugs
Year: 2007, type: Conference abstract
-
Kompenzují nové léky vliv cytogenetických negativních prognostických markerů u pacientů s mnohočetným myelomem?
Sborník abstrakt, XXI. Olomoucké hematologické dny s mezinárodní účastí, year: 2007
-
Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval
Blood 2007, Vol.110(11) Part 2, year: 2007
-
Prognostic impact of 1q21 amplification for newly diagnosed and relapsed/refractory multiple myeloma patients enrolled in Brno, Czech Republic.
From cell sorting to plasma cell identification and detection chromosomal aberrations in multiple myeloma. Abstract and Application Manual, year: 2007
-
Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy
Blood Reviews, year: 2007
-
Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade)
Hematologica/The Hematology Journal, year: 2007
-
Prognostic value of selected chromosomal abnormalities in multiple myeloma patients treated by thalidomide
Haematologica, year: 2007
-
Prognostický význam amplifikace 1q21 u pacientů s mnohočetným myelomem léčených bortezomibem (Velcade), thalidomidem (Myrin) a konvenční chemoterapií
Year: 2007, type: Conference abstract